BSP Medical Ltd.

www.bspmedical.com

Formerly BSP Biological Signal Processing

High-Tech Company

Acquired by ICB

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	1999
Number of Employees	8
Reg. Number:	abCDe

DESCRIPTION

BSP is dedicated to providing novel, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. Using proprietary signal processing technology, BSP's products perform analysis of the high-frequency QRS components for more sensitive and accurate results than conventional stress testing.

TECHNOLOGY

HyperQ™ Technology - The physiological significance of the high frequency components of the QRS complex was first described in the 1980’s. Since then, it has been extensively researched and clinically validated as an important diagnostic tool. The technology used for the HyperQ™ analysis detects and probes the high frequency components of the QRS complex.

Products and Phases

Product	Phase
HyperQ EX-300	FDA Approved CE Approved
HyperQ Stress System is a unique PC-based ECG system that offers clinicians reliable diagnosis of ischemic heart diseases.
HyperQ™ RE-200 Rest System	FDA Approved CE Approved
A 12 lead rest ECG system which enables unlimited recording of ECG data with an advanced ECG filtering, events capture and comprehensive printouts.
HyperQ AD-100	FDA Approved CE Approved
An add-on device to an existing electrocardiogram (ECG) stress system.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	ECG Device Manufacturers, Implantable Device Manufacturers, Health Service Organizations, Cardiologist’s Clinics.

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm

REMARKS

Date

Remark

BSP has been in the biotech industry for many years. In 2017, Mr. Huang Qingxi, a Chinese investor, took control of the company, and the board of directors shifted priority to become an investment company in the biomedical field. In 2018 the company changed its name to ICB Biotechnology Investments Ltd. (ICB). It shifted business strategy to become a leading high-tech healthcare investor in Israeli medical companies that directly provides funding to pave the way for Israeli companies into China, the biggest emerging market in the world. In Early 2019 ICB transferred BSP's previous technological activity in the field of diagnosis and monitoring of Ischemic Heart Disease to its subsidiary BSP Medical.

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	22a Wallenberg St.
City	Tel Aviv
Country	Israel
Zip	6971917

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Brookline, United States

Address	40 Williams St.
City	Brookline
State/Province	MA
Country	United States
Zip	02446

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Ningzhou Zhang	CEO	ICB (CEO)
Mr. Yehuda Bruner	COO
Prof. Shimon Abboud	Chief Scientific Consultant
Mr. Guy Goldin	CFO	SciSparc (CFO)
Dr. Amir Beker	Founder	Balm (CEO)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Investor, BSP - Biological Signal Processing
abC Defghij	Board Member	CEO, BSP - Biological Signal Processing
abC Defghij	External Director	Former Co-Ceo, Hilan-Tech
abC Defghij	External Director	Director of the Heart Institute, Sheba Medical Center
abC Defghij	Chairman of Scientific Advisory Board	Director of the Cardiovascular Center, the University of California
abC Defghij	Board Member	Professor of Medicine, University of California
abC Defghij	Scientific Advisor	Professor of Cardiology and Professor of Internal Medicine, University of Virginia Health System
abC Defghij	Scientific Advisor	Assistant Professor of Medicine, the Mayo Clinic Rochester
abC Defghij	Scientific Advisor	Cardiologist, Medical Director, the Women’s Heart Center
abC Defghij	Scientific Advisor	Director of the Cardiac Intensive Care Unit, Division of Cardiovascular Disease, Washington University School of Medicine
abC Defghij	Scientific Advisor	Director of the Cardiovascular Catheterization Laboratories, Fletcher Allen Health Care

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Oct. 27, 2017

Initial Revenues

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Feb. 11, 2011	Third Public Offering	TASE	abCDe	abCDe
Jul. 28, 2010	Second Public Offering	TASE	abCDe	abCDe
May. 16, 2006	IPO	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Dec. 21, 2014

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe

PIPE

Feb. 01, 2010

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe	Holds 2.18% of the company
abC Defghij	Private Investor	abCDe	Holds 6.63% of the company
abC Defghij	Private Investor	abCDe	Holds 1.83% of the company
abC Defghij	Other	abCDe	Holds 9.39% of the company
abC Defghij	Other	abCDe	Holds 6.71% of the company through his company, Stonehill Ltd.
abC Defghij	Private Investor	abCDe	Holds 10.69% of the company
abC Defghij	Other	abCDe	Through Agrippa Associates Ltd. (his private firm)
abC Defghij	Private Investor	abCDe	Holds 5.88% of the company
abC Defghij	Private Investor	abCDe	Holds 3.1% of the company
abC Defghij	Other	abCDe	Holds 5.47% of the company; Held 50% by Meir Shani
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe	Holds 2.84% of the company

PIPE

Jun. 01, 2008

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

First Round

Dec. 01, 2004

R&D

abCDe

Seed

Oct. 01, 2003

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Dec. 31, 2017

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe
abC Defghij	N/A	abCDe

R&D Grant

Nov. 08, 2010

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-Lateral R&D Program	abCDe	Co-op with Schiller AG

R&D Grant

May. 17, 2009

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Apr. 01, 2006

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Nov. 30, 2005

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Business Development Company	abCDe

R&D Grant

Jan. 20, 2004

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Oct. 01, 2002

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Oct. 01, 2000

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe